CLINUVEL
Posted by CLINUVEL
October 26, 2020

Update: SCENESSE® in DNA Repair

CLINUVEL PHARMACEUTICALS LTD provided today a clinical update on the use of...

Read More
CLINUVEL
Posted by CLINUVEL
October 26, 2020
CLINUVEL
Posted by CLINUVEL
October 9, 2020

CLINUVEL Annual General Meeting 2020

CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on...

Read More
CLINUVEL
Posted by CLINUVEL
September 16, 2020
CLINUVEL
Posted by CLINUVEL
September 14, 2020

Media Release - First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...

Read More
CLINUVEL
Posted by CLINUVEL
September 14, 2020

First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program

Drug tested to protect skin and regenerate DNA, firstly in XP patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release – New drug to repair damaged skin and reduce skin cancer risk

Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...

Read More
CLINUVEL
Posted by CLINUVEL
August 27, 2020
CLINUVEL
Posted by CLINUVEL
August 27, 2020

CLINUVEL Full Year Results 2020

CLINUVEL REPORTS PROFIT, RENVESTING IN BUSINESS Fourth consecutive annual positive net cash...

Read More
CLINUVEL
Posted by CLINUVEL
July 31, 2020
CLINUVEL
Posted by CLINUVEL
July 8, 2020

Lapse and Forfeit of Unlisted Conditional Performance Rights

CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and...

Read More